Skip to main content

Table 2 Comparison of endocrine and gynecologic diagnoses at adulthood

From: Gonadotropin releasing hormone analogue treatment of central precocious puberty is not associated with altered prevalence of polycystic ovary syndrome: a single center cohort study

Parameter

GnRHa treatment

N = 27

No treatment

N = 24

P value

Hypothyroidism

1 (3.7)

1 (4.2)

1.00

Osteoporosis

0

1 (4.2)

0.471

Hyperinsulinism

1 (3.7)

0

1.00

Height (cm)

160.8 ± 4.6 (152–170)

154.8 ± 10.2 (130–170)

0.026

Delta height compared to mid-parental height

-2.8 ± 5.1 (-13-(+ 16.5))

-6.3 ± 7.4 (-24-(+ 2))

0.154

BMI (kg/m2)

24.8 ± 5.6 (19.4–40.0)

23.6 ± 3.4 (14.4–30.9)

0.865

PCOS diagnosisa

7 (25.9)

3 (12.5)

0.300

Hyper-androgenismb

8 (29.6)

7 (29.2)

0.971

Menorrhagia

2 (7.4)

4 (16.7)

0.402

Metrorrhagia

1 (3.7)

2 (8.3)

0.596

Menses

  

0.671

 Regular

17 (63.0)

17 (70.8)

 

 Oligomenorrhea

8 (29.6)

7 (29.2)

 

 Amenorrhea

2 (7.4)

0

 
  1. Data presented as Mean ± SD or n (%)
  2. Note: PCOS Polycystic Ovary Syndrome, BMI Body Mass Index
  3. a According to the Androgen Excess Society Criteria (2006)
  4. b Either clinical or laboratory based hyperandrogenism diagnosis